Edwards(US:EW) ZACKS·2026-02-05 15:16Core Viewpoint - Analysts project that Edwards Lifesciences will report quarterly earnings of $0.62 per share, reflecting a year-over-year increase of 5.1%, with revenues expected to reach $1.54 billion, an 11.1% increase from the same quarter last year [1]. Earnings Projections - The consensus EPS estimate has been revised upward by 0.7% in the past 30 days, indicating a reassessment of initial estimates by covering analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Key Metrics Estimates - Analysts estimate 'Net Sales by Product Group - Transcatheter Mitral and Tricuspid Therapies' will reach $151.63 million, a 44.3% increase year-over-year [5]. - The consensus for 'Net Sales by Product Group - Surgical Structural Heart' is $259.76 million, suggesting a 6.3% year-over-year change [5]. - 'Net Sales by Product Group - Transcatheter Aortic Valve Replacement' is projected at $1.13 billion, reflecting an 8.9% increase from the previous year [6]. - 'Net Sales - Europe' is estimated at $385.24 million, indicating a 12.1% year-over-year change [6]. - 'Net Sales - Outside of the United States' is expected to be $656.66 million, a 14.6% increase year-over-year [7]. - 'Net Sales - United States' is projected at $881.08 million, reflecting an 8.4% increase from the year-ago quarter [7]. - 'Net Sales - Japan' is estimated to reach $92.30 million, indicating a 7.5% year-over-year change [7]. - 'Net Sales - Rest of World' is projected at $179.12 million, reflecting a 25% increase from the previous year [8]. Stock Performance - Edwards Lifesciences shares have decreased by 6% over the past month, contrasting with the Zacks S&P 500 composite's increase of 0.5%, and the company holds a Zacks Rank 3 (Hold), suggesting it will closely follow overall market performance in the near term [8].